IS7314A - 5,6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists - Google Patents
5,6-diaryl-pyrazine-2-amide derivatives as cb1 antagonistsInfo
- Publication number
- IS7314A IS7314A IS7314A IS7314A IS7314A IS 7314 A IS7314 A IS 7314A IS 7314 A IS7314 A IS 7314A IS 7314 A IS7314 A IS 7314A IS 7314 A IS7314 A IS 7314A
- Authority
- IS
- Iceland
- Prior art keywords
- diaryl
- pyrazine
- antagonists
- amide derivatives
- amide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0104330A SE0104330D0 (en) | 2001-12-19 | 2001-12-19 | Therapeutic agents |
| PCT/GB2002/005742 WO2003051851A1 (en) | 2001-12-19 | 2002-12-18 | 5, 6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IS7314A true IS7314A (en) | 2004-06-16 |
Family
ID=20286429
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS7314A IS7314A (en) | 2001-12-19 | 2004-06-16 | 5,6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US7342019B2 (en) |
| EP (1) | EP1458690B1 (en) |
| JP (1) | JP2005517655A (en) |
| KR (1) | KR20040068286A (en) |
| CN (1) | CN1620438A (en) |
| AR (1) | AR038044A1 (en) |
| AT (1) | ATE354570T1 (en) |
| AU (1) | AU2002352425A1 (en) |
| BR (1) | BR0214989A (en) |
| CA (1) | CA2469786A1 (en) |
| CO (1) | CO5590917A2 (en) |
| DE (1) | DE60218340T2 (en) |
| ES (1) | ES2280599T3 (en) |
| HU (1) | HUP0402026A3 (en) |
| IL (1) | IL162377A0 (en) |
| IS (1) | IS7314A (en) |
| MX (1) | MXPA04005990A (en) |
| NO (1) | NO20043022L (en) |
| NZ (1) | NZ533275A (en) |
| PL (1) | PL369731A1 (en) |
| RU (1) | RU2004116916A (en) |
| SE (1) | SE0104330D0 (en) |
| TW (1) | TW200410694A (en) |
| WO (1) | WO2003051851A1 (en) |
| ZA (1) | ZA200404805B (en) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7704995B2 (en) | 2002-05-03 | 2010-04-27 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| GB0216700D0 (en) | 2002-07-18 | 2002-08-28 | Astrazeneca Ab | Process |
| US7405221B2 (en) | 2002-09-27 | 2008-07-29 | Merck & Co., Inc. | Substituted pyrimidines |
| US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
| US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| GB0230088D0 (en) * | 2002-12-24 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
| GB0302671D0 (en) * | 2003-02-06 | 2003-03-12 | Astrazeneca Ab | Pharmaceutical formulations |
| GB0302673D0 (en) | 2003-02-06 | 2003-03-12 | Astrazeneca Ab | Pharmaceutical formulations |
| US7176210B2 (en) | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US7141669B2 (en) | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
| US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US7268133B2 (en) | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
| US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| GB0314057D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0314049D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| WO2004111033A1 (en) * | 2003-06-18 | 2004-12-23 | Astrazeneca Ab | 2-substitued 5, 6-diaryl-pyrazine derivatives as cb1 modulator. |
| GB0314261D0 (en) * | 2003-06-19 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| US20050014786A1 (en) | 2003-07-11 | 2005-01-20 | Chongqing Sun | Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
| US7326706B2 (en) * | 2003-08-15 | 2008-02-05 | Bristol-Myers Squibb Company | Pyrazine modulators of cannabinoid receptors |
| CA2537535A1 (en) * | 2003-09-02 | 2005-03-10 | Solvay Pharmaceuticals Gmbh | Novel medical use of selective cb1-receptor antagonists |
| US7320805B2 (en) * | 2003-10-01 | 2008-01-22 | Institut National De La Sante Et De La Recherche Medicale | CB2 receptors blocks accumulation of human hepatic myofibroblasts: a novel artifibrogenic pathway in the liver |
| WO2005037199A2 (en) | 2003-10-10 | 2005-04-28 | Bristol-Myers Squibb Company | Pyrazole derivatives as cannabinoid receptor modulators |
| AR046132A1 (en) * | 2003-10-24 | 2005-11-23 | Solvay Pharm Gmbh | PHARMACEUTICAL COMPOSITION CONTAINING AT LEAST ONE COMPOUND WITH RECEIVER ACTIVITY OF CB1, OR A PROFARMACO, TAUTOMERO OR SALT OF THE SAME, AS A SUITABLE ACTIVE COMPONENT FOR THE TREATMENT AND / OR PROFILAXIS OF DISEASES RELATED TO THE RECEIVER CB1 IN PATIENTS OR YOUTH PATIENTS THE TREATMENT |
| CN1867332A (en) * | 2003-10-24 | 2006-11-22 | 索尔瓦药物有限公司 | Combination treatment of obesity involving selective cb1-antagonists and lipase inhibitors |
| GB0327331D0 (en) * | 2003-11-25 | 2003-12-31 | Astrazeneca Ab | Therapeutic agents |
| EP1734963A4 (en) | 2004-04-02 | 2008-06-18 | Merck & Co Inc | Method of treating men with metabolic and anthropometric disorders |
| TW200602314A (en) | 2004-05-28 | 2006-01-16 | Tanabe Seiyaku Co | A novel pyrrolidine compound and a process for preparing the same |
| CA2585175A1 (en) | 2004-10-25 | 2006-05-04 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising cb1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type i, obesity and related conditions |
| ES2326280T3 (en) | 2005-04-06 | 2009-10-06 | F. Hoffmann-La Roche Ag | DERIVATIVES OF PIRIDIN-3-CARBOXAMIDE AS INVESTED AGONISTS OF CB1. |
| AR053712A1 (en) * | 2005-04-18 | 2007-05-16 | Neurogen Corp | HETEROARILOS SUBSTITUTED, ANTAGONISTS OF CB1 (RECEIVER 1 CANABINOID) |
| EP2308840A1 (en) | 2005-06-30 | 2011-04-13 | Prosidion Limited | GPCR agonists |
| US7629346B2 (en) | 2006-06-19 | 2009-12-08 | Hoffmann-La Roche Inc. | Pyrazinecarboxamide derivatives as CB1 antagonists |
| US7781593B2 (en) | 2006-09-14 | 2010-08-24 | Hoffmann-La Roche Inc. | 5-phenyl-nicotinamide derivatives |
| EP2074096B1 (en) * | 2006-10-04 | 2012-06-27 | F. Hoffmann-La Roche AG | 3-pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as hdl-cholesterol raising agents |
| AR064735A1 (en) | 2007-01-04 | 2009-04-22 | Prosidion Ltd | GPCR AGONISTS AND PHARMACEUTICAL COMPOSITION BASED ON THE COMPOUND |
| BRPI0806312A2 (en) | 2007-01-04 | 2011-09-06 | Prosidion Ltd | cgpr piperidine agonists |
| ATE523507T1 (en) | 2007-01-04 | 2011-09-15 | Prosidion Ltd | PIPERIDINE GPCR AGONISTS |
| PE20081849A1 (en) | 2007-01-04 | 2009-01-26 | Prosidion Ltd | PIPERIDIN-4-IL-PROPOXY-BENZAMIDE DERIVATIVES AS GPCR AGONISTS |
| GB0700122D0 (en) | 2007-01-04 | 2007-02-14 | Prosidion Ltd | GPCR agonists |
| GB0720389D0 (en) | 2007-10-18 | 2008-11-12 | Prosidion Ltd | G-Protein Coupled Receptor Agonists |
| GB0720390D0 (en) | 2007-10-18 | 2007-11-28 | Prosidion Ltd | G-Protein coupled receptor agonists |
| WO2010079241A1 (en) | 2009-01-12 | 2010-07-15 | Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion | Use of antagonists and/or inverse agonists of cb1 receptors for the preparation of drugs that increase motor neuron excitability |
| US8410107B2 (en) | 2010-10-15 | 2013-04-02 | Hoffmann-La Roche Inc. | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides |
| US8669254B2 (en) | 2010-12-15 | 2014-03-11 | Hoffman-La Roche Inc. | Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents |
| US9403808B2 (en) * | 2011-10-28 | 2016-08-02 | Hoffmann-La Roche Inc. | Pyrazine derivatives |
| IL300394A (en) | 2020-08-06 | 2023-04-01 | Chdi Foundation Inc | Heterobiaryl compounds and imaging agents for imaging huntingtin protein |
| WO2024159286A1 (en) * | 2023-01-30 | 2024-08-08 | Eurofarma Laboratórios S.A. | Nav1.7- and/or nav1.8-inhibiting phenolic compounds, processes for the preparation thereof, compositions, uses, methods for treatment using same, and kits |
| WO2024159284A1 (en) * | 2023-01-30 | 2024-08-08 | Eurofarma Laboratórios S.A. | Nav1.7- and/or nav1.8-inhibiting hydrazides, processes for the preparation thereof, compositions, uses, methods for treatment using same, and kits |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH458361A (en) * | 1965-01-15 | 1968-06-30 | Eprova Ag | Process for the preparation of pyrazine carboxylic acids |
| JPS5322529A (en) * | 1976-08-13 | 1978-03-02 | Nippon Soda Co Ltd | Dihydropyrazine derivative and its preparation |
| EP0397859A4 (en) * | 1987-11-12 | 1990-12-19 | Terumo Kabushiki Kaisha | Pyrazine derivatives and medicinal preparation containing same |
| WO1992002513A1 (en) | 1990-08-06 | 1992-02-20 | Fujisawa Pharmaceutical Co., Ltd. | Heterocyclic compounds |
| FR2713225B1 (en) * | 1993-12-02 | 1996-03-01 | Sanofi Sa | Substituted N-piperidino-3-pyrazolecarboxamide. |
-
2001
- 2001-12-19 SE SE0104330A patent/SE0104330D0/en unknown
-
2002
- 2002-12-18 CN CNA028281535A patent/CN1620438A/en active Pending
- 2002-12-18 CA CA002469786A patent/CA2469786A1/en not_active Abandoned
- 2002-12-18 MX MXPA04005990A patent/MXPA04005990A/en unknown
- 2002-12-18 EP EP02788143A patent/EP1458690B1/en not_active Expired - Lifetime
- 2002-12-18 HU HU0402026A patent/HUP0402026A3/en unknown
- 2002-12-18 RU RU2004116916/04A patent/RU2004116916A/en not_active Application Discontinuation
- 2002-12-18 DE DE60218340T patent/DE60218340T2/en not_active Expired - Fee Related
- 2002-12-18 BR BR0214989-3A patent/BR0214989A/en not_active IP Right Cessation
- 2002-12-18 PL PL02369731A patent/PL369731A1/en not_active Application Discontinuation
- 2002-12-18 AU AU2002352425A patent/AU2002352425A1/en not_active Abandoned
- 2002-12-18 US US10/499,054 patent/US7342019B2/en not_active Expired - Fee Related
- 2002-12-18 JP JP2003552736A patent/JP2005517655A/en active Pending
- 2002-12-18 ES ES02788143T patent/ES2280599T3/en not_active Expired - Lifetime
- 2002-12-18 WO PCT/GB2002/005742 patent/WO2003051851A1/en active IP Right Grant
- 2002-12-18 NZ NZ533275A patent/NZ533275A/en unknown
- 2002-12-18 KR KR10-2004-7009589A patent/KR20040068286A/en not_active Application Discontinuation
- 2002-12-18 AT AT02788143T patent/ATE354570T1/en not_active IP Right Cessation
- 2002-12-18 IL IL16237702A patent/IL162377A0/en unknown
- 2002-12-19 AR ARP020105001A patent/AR038044A1/en not_active Application Discontinuation
- 2002-12-19 TW TW091136671A patent/TW200410694A/en unknown
-
2004
- 2004-06-16 IS IS7314A patent/IS7314A/en unknown
- 2004-06-17 ZA ZA200404805A patent/ZA200404805B/en unknown
- 2004-07-09 CO CO04065292A patent/CO5590917A2/en not_active Application Discontinuation
- 2004-07-15 NO NO20043022A patent/NO20043022L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20040068286A (en) | 2004-07-30 |
| EP1458690B1 (en) | 2007-02-21 |
| EP1458690A1 (en) | 2004-09-22 |
| NZ533275A (en) | 2006-02-24 |
| NO20043022L (en) | 2004-07-15 |
| MXPA04005990A (en) | 2004-09-27 |
| WO2003051851A1 (en) | 2003-06-26 |
| AR038044A1 (en) | 2004-12-22 |
| TW200410694A (en) | 2004-07-01 |
| US7342019B2 (en) | 2008-03-11 |
| HUP0402026A3 (en) | 2005-08-29 |
| ZA200404805B (en) | 2005-08-15 |
| IL162377A0 (en) | 2005-11-20 |
| CA2469786A1 (en) | 2003-06-26 |
| BR0214989A (en) | 2004-12-14 |
| DE60218340T2 (en) | 2007-11-29 |
| JP2005517655A (en) | 2005-06-16 |
| CN1620438A (en) | 2005-05-25 |
| PL369731A1 (en) | 2005-05-02 |
| ATE354570T1 (en) | 2007-03-15 |
| ES2280599T3 (en) | 2007-09-16 |
| CO5590917A2 (en) | 2005-12-30 |
| US20050032808A1 (en) | 2005-02-10 |
| SE0104330D0 (en) | 2001-12-19 |
| AU2002352425A1 (en) | 2003-06-30 |
| RU2004116916A (en) | 2005-11-10 |
| HUP0402026A2 (en) | 2005-02-28 |
| DE60218340D1 (en) | 2007-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IS7314A (en) | 5,6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists | |
| DK1429761T3 (en) | New 4,5-dihydro-1H-pyrazole derivatives with CB1 antagonistic effect | |
| NO20032892D0 (en) | 4,5-dihydro-1H-pyrazole derivatives with CB1 antagonistic effect | |
| IS8226A (en) | 3-substituted 5,6-diaryl-pyrazine-2-carboxamide and -2-sulfonamide derivatives which CB1 adjusts | |
| CY2014041I1 (en) | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-B-OXAZOLE | |
| DE60214428D1 (en) | 1, 4-DIHYDRO-1, 4-DIPHENYLPYRIDINE DERIVATIVES | |
| NO20041170L (en) | 4,5-dihydro-1H pyrazole derivatives with potent CB1 antagonistic activity | |
| NO20041075L (en) | New 1,2,4-triazole compound | |
| IS7328A (en) | Replaced quinazoline derivatives which inhibit aerokinases | |
| HK1068339A1 (en) | Dihydro-benzo ÄbÜ Ä1,4Üdiazepin-2-one derivatives as mglur2 antagonists i | |
| SI1699795T1 (en) | SUBSTITUTED 8'-PYRI(MI)DINYL-DIHYDROSPIRO-?áCYCLOALKLYMINE?å-PYRIMIDO?á1,2A?åPYRIMIDIN-6-ONE DERIVATIVES | |
| IL153224A0 (en) | 1,4-dihydropyridines as bradykinin antagonists | |
| IS7187A (en) | 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists | |
| MXPA03006991A (en) | Piperidinee derivatives as neurokinin 1 antagonists. | |
| ATE326467T1 (en) | IMIDAZO 1,2-AÖPYRIDINE | |
| IS7060A (en) | 2,5-diarylpyrazine, 2,5-diarylpyridine and 2,5-diarylpyrimidine as CRF1 receptors | |
| DE50107988D1 (en) | SUBSTITUTED 1,2,3,4-TETRAHYDROCHINOLIN-2-CARBOXYLENE DERIVATIVES | |
| DE60025958D1 (en) | 14,15-BETA-METHYLENE SUBSTITUTED ANDROGENE | |
| ID27845A (en) | TETRAHIDROKUILINA DECREASED AS GLISILINA ANTAGONISTS | |
| NO20042980L (en) | 3,4-dihydro-1H-isoquinolin-2-yl derivatives | |
| MA27240A1 (en) | IMIDAZOQUINOLEIN DERIVATIVES | |
| NO20044405L (en) | Neurotensinactive 2,3-diaryl-pyrazolidine derivatives | |
| IS7131A (en) | New 2,4-diaminothiazole derivatives | |
| ATE470655T1 (en) | SUBSTITUTED 1,5-DIAMINOPENTANE-3-OL COMPOUNDS | |
| IS7299A (en) | 3,4-dihydro-1H-isoquinolone-2-yl derivatives |